Aurobindo Pharma’s arm signs deal to set up JV in China

31 Aug 2019 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Helix Healthcare S.V, Netherlands, has entered into an agreement on August 29, 2019 with Shanghai LongJin Investment Company, China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of 'Longxiang Pharma Taizhou Co  for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1155.60 -13.30 (-1.14%)
02-Feb-2026 11:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1600.65
Dr. Reddys Lab 1170.25
Cipla 1295.10
Zydus Lifesciences 866.15
Lupin 2085.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×